Equidyne-Wechsel in Nasdaq - 500 Beiträge pro Seite

[Bernd.Foertsch]

Equidyne hat wie in meinem letzten Beitrag den Wechsel von OTC in das Nasdaq National Segment beantragt.

Jetzt geht`s los. (Siehe Kursverlauf)

[Fernd.Boertsch]

Quelle bitte

[Mo2]

Company Press Release
Equidyne Corporation Files for Nasdaq National Market Listing
WESTFORD, Mass.--(BW HealthWire)--March 22, 2000--EQUIDYNE CORPORATION (OTCBB:INJX - news) announced today the filing of its application with the The Nasdaq Stock Market, Inc. for its shares of common stock to be traded on the Nasdaq National Market system. Equidyne`s shares are currently being traded on the OTC Bulletin Board under the symbol INJX.

J. Randall Nelson, President and Chief Executive Officer, stated, ``We believe we have met the financial listing qualifications required for our shares to be traded on the NASDAQ National Market and look forward to the approval of our application. We are excited about the prospect of having our stock traded on a more broadly followed market with the prestigious reputation of NASDAQ. This planned listing will expose Equidyne and its INJEX(TM) needle-free System to a much broader group of investors, many of whom have been precluded from acquiring our stock, and allow for new market makers to sponsor Equidyne`s stock. We believe this NASDAQ market listing will allow for a more accurate valuation of our INJEX(TM) technology and the additional value created as a result of the successful IPO of our partially-owned investment Rosch AG Medizintechnik.``

[RayDee]

Hi Leute,

hat jemand von euch eine Ahnung, wie lange sowas dauert, bis entschieden ist, ob Equidyne nun in den NASDAQ aufgenommen wird oder nicht?

Greets und keine kalten Füße bekommen bei dem Markt ...
Rayd

[heko1]

hi Leute

Equidyne ist von Aktienchek in Ihrem neuen Report21
Heft 2 mit KZ von bis zu 20$ empfohlen worden.
Beteiligung an Roesch AG Medizintechnik beträgt 26%.
INJEX Patente weltweit,Roesch nur in Europa.

[Tippo]

es ist schon ruhig geworden um Rösch und Equidyne. Die Titel waren ja fürchterlich
überreitzt. Sollte eigentlich Titel erst dann ins Depot nehmen, wenn die Postings auf nahe O fallen.
Bin der Meinung, dass die beiden die Kurve schon noch kriegen. Bei Equidyne bin ich mir sicher, dass
jemand massiv am Tanken ist, - das geht ein paar Wochen und dann hagelt es Empfehlungen. Ist halt immer das
gleiche Spielchen dass Institutionelle mit den Kleinanlegern machen.
Jetzt will Equidyne Einmalspritzen(Patent) machen. Kann mir jetzt gut vorstellen, dass es nun noch mehr Changen gibt
die Dinger zu einem weltweiten Massenprodukt aufsteigen zulassen.
Na, was meint Ihr zur folgenden Ankündigung:

Equidyne Corporation Announces Development of
Disposable Injector

WESTFORD, Mass.--(BW HealthWire)--April 12, 2000--
-New Single Use INJEX(TM) to Compete With Safety Needles and
Reduce Hospital and Clinic Costs-
EQUIDYNE CORPORATION (OTCBB:INJX) announced today the filing of a
Patent application with the U.S. Patent and Trademark Office for a new
single-use, disposable, needle-free injector. This revolutionary
device will incorporate our current needle-free ampule technology
contained in a completely disposable device no larger than a ballpoint
pen. The new INJEX(TM) disposable drug delivery device will compete in
a market for needle syringes that exceeds $2 Billion and is expected
to be introduced to the mass marketplace in commercial quantities
before the end of 2000.
Commenting on the announcement, J. Randall Nelson, President and
Chief Executive Officer of Equidyne, stated, "We believe that this
revolutionary development gives Equidyne`s family of needle-free
delivery systems a single use disposable injector that is economically
competitive with today`s "so-called" safety needles, without the
inherent disadvantages of a needle. There are a variety of compelling
applications for the new INJEX(TM) disposable system, including
heparin injections for post-surgical patients and outpatient treatment
in oncology, both of which will reduce overall costs by minimizing
hospital stays and/or clinic visits. Gestational diabetes, which is
usually short term during pregnancy, is another excellent opportunity
for this new application."
Equidyne Corporation, through Equidyne Systems, Inc., a
wholly-owned subsidiary based in San Diego, California, and Rosch AG
Medizintechnik, its partially-owned investment based in Berlin,
Germany (Additional information at: www.roeschnet.com), is focused on
becoming the worldwide leader in needle-free drug delivery systems for
subcutaneous and intramuscular injections. Equidyne is responsible for
the U.S., Canada, South America and the Asian markets while Rosch AG
is responsible for the European market. The INJEX(TM) needle-free
injector is a compact, uncomplicated device that delivers a virtually
painless injection through the skin in a fraction of a second, and
eliminates needle stick and disposal problems. For medications
requiring injection, we believe the INJEX(TM) System is by far the
most comfortable and economical product on the market.
The statements contained in this news release that are not purely
historical are forward-looking statements that may involve risks and
uncertainties. The Company`s actual results may differ significantly
from the results contained in the forward-looking statements. Factors
that might cause such differences include, but are not limited to, the
effect of losses and other factors on the Company`s credit facilities,
business and results of operations; the Company`s limited capital
resources and its ability to fulfill its existing obligations and
ongoing capital needs; risks associated with excess or obsolete
inventory; the potential impairment of assets; the Company`s
dependence on key customers and their financial viability; the impact
of competition; and the Company`s abilities to effectively manage
growth. These and other risk factors are discussed in the Company`s
filings on Forms 8-K, 10-QSB and 10-KSB.
--30--mb/bos*
CONTACT: Equidyne Corporation
Michael T. Pieniazek, Executive VP
[phone]
or
American Financial Communications
Jeffery Lamberson or Richard Carpenter
[phone]

Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.
URL: http://www.businesswire.com